Education
About Us
Working with TipRanks
Follow Us
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
:GPCR
RESEARCH TOOLSreports
GPCR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$18.87 - $62.74
Previous CloseN/A
Volume219.80K
Average Volume (3M)760.15K
Market Cap
$1.13B
Enterprise Value$1.60B
Total Cash (Recent Filing)$105.31K
Total Debt (Recent Filing)$621.00
Price to Earnings (P/E)―
Beta1.37
Next Earnings
May 08, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.32
Shares Outstanding57,342,846
10 Day Avg. Volume605,304
30 Day Avg. Volume760,147
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)62.00
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.18
Forecast
1Y Price Target
$83.88Price Target Upside324.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Structure Therapeutics, Inc. Sponsored ADR News
---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company has a substantial cash balance of $883.5M, expected to fund operations through at least 2027.
Market PositionAleniglipron could position itself as a significant competitor on both tolerability and efficacy.
Pipeline PotentialGPCR continues to offer significant pipeline optionality, indicating potential future growth opportunities.
Bears Say
Market CompetitionPhase 3 data from Eli Lilly’s orforglipron may put pressure on the stock and provide an attractive opportunity ahead of GPCR’s data.
Stock ValuationThe price target for GPCR has been lowered from $93 to $60 due to increased competition.
---
Ownership Overview
10.34% Insiders
39.22% Mutual Funds
<0.01% Other Institutional Investors
49.39% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $18.87 and its highest was $62.74 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $1.13B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is May 08, 2025 which is in 36 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Feb 27, 2025. The company reported -$0.211 earnings per share for the quarter, beating the consensus estimate of -$0.224 by $0.013.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.24.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 57,342,846 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of -$0.211 in its last earnings report, beating expectations of -$0.224. Following the earnings report the stock price went up 4.075%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
---
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$83.88 (324.28% Upside)
$83.88 (324.28% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.61%
12-Months-Change
Fundamentals
Return on Equity
-18.61%
Trailing 12-Months
Asset Growth
87.41%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
---
GPCR Stock 12 Month Forecast
Average Price Target
$83.88
▲(324.28% Upside)
Technical Analysis
Best Analysts Covering GPCR
1 Year
1 Year Success Rate
5/15 ratings generated profit
1 Year Average Return
-7.59%
reiterated a buy rating last month
Copying David Risinger's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -7.59% per trade.
---